成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart 0 Sign in  

[ CAS No. 763111-47-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 763111-47-3
Chemical Structure| 763111-47-3
Structure of 763111-47-3 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 763111-47-3 ]

Related Doc. of [ 763111-47-3 ]

Alternatived Products of [ 763111-47-3 ]
Product Citations

Product Citations

Beha, Marcel Janis ; Kim, Joo-Chan ; Im, San Hae , et al. DOI: PubMed ID:

Abstract: Bioconjugation of proteins can substantially expand the opportunities in biopharmaceutical development, however, applications are limited for the gene editing machinery despite its tremendous therapeutic potential. Here, a self-delivered nanomedicine platform based on bioorthogonal CRISPR/Cas9 conjugates, which can be armed with a chemotherapeutic drug for combinatorial therapy is introduced. It is demonstrated that multi-functionalized Cas9 with a drug and polymer can form self-condensed nanocomplexes, and induce significant gene editing upon delivery while avoiding the use of a conventional carrier formulation. It is shown that the nanomedicine platform can be applied for combinatorial therapy by incorporating the anti-cancer drug olaparib and targeting the RAD52 gene, leading to significant anti-tumor effects in BRCA-mutant cancer. The current development provides a versatile nanomedicine platform for combination treatment of human diseases such as cancer.

Keywords: bioorthogonal ; cancer therapy ; chemotherapeutic drugs ; combinatorial delivery ; CRISPR ; Cas9 ; gene editing ; nanomedicines ; unnatural amino acids

Purchased from AmBeed:

Product Details of [ 763111-47-3 ]

CAS No. :763111-47-3 MDL No. :MFCD18251631
Formula : C20H19FN4O2 Boiling Point : -
Linear Structure Formula :- InChI Key :MFFUYEOGICAKCK-UHFFFAOYSA-N
M.W : 366.39 Pubchem ID :11726399
Synonyms :
Chemical Name :4-(4-Fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one

Calculated chemistry of [ 763111-47-3 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 27
Num. arom. heavy atoms : 16
Fraction Csp3 : 0.25
Num. rotatable bonds : 4
Num. H-bond acceptors : 5.0
Num. H-bond donors : 2.0
Molar Refractivity : 107.8
TPSA : 78.09 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.46 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.57
Log Po/w (XLOGP3) : 1.52
Log Po/w (WLOGP) : 1.36
Log Po/w (MLOGP) : 2.7
Log Po/w (SILICOS-IT) : 3.84
Consensus Log Po/w : 2.4

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -3.24
Solubility : 0.209 mg/ml ; 0.000571 mol/l
Class : Soluble
Log S (Ali) : -2.77
Solubility : 0.625 mg/ml ; 0.0017 mol/l
Class : Soluble
Log S (SILICOS-IT) : -6.83
Solubility : 0.0000541 mg/ml ; 0.000000148 mol/l
Class : Poorly soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.86

Safety of [ 763111-47-3 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 763111-47-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 763111-47-3 ]

[ 763111-47-3 ] Synthesis Path-Downstream   1~3

  • 1
  • [ 763111-47-3 ]
  • [ 1798-06-7 ]
  • 4-(4-fluoro-3-(4-(2-(4-iodophenyl)acetyl)piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one [ No CAS ]
YieldReaction ConditionsOperation in experiment
61% EXAMPLE A.5. A solution of 4-iodophenyl acetic acid (6.5 mg, 0.048 mmol), EDC (10.5 mg, 0.055 mmol), NHS and 600 μ DMF was stirred for 30 min at room temperature. After this time, the 4-(4-fluoro-3- (piperazine-l-carbonyl)benzyl)phthalazin-l(2H)-one (10 mg, 0.0275 mmol) was added to the solution and the mixture was stirred at room temperature overnight. H20 (500 μ) was added, the mixture extracted with DCM (2 x 500 μ), and the combined extracts dried under vacuum. The crude mixture was purified by silica column chromatography (100% DCM), and the product obtained as a white solid (8.8 mg, 61%). 1H NMR (CDCI3) δ = 9.82 (s, 1H), 8.40-8.38 (m, 1H), 7.83-7.81 (d, 1H), 7.77- 7.75 (d, 1H), 7.70-7.69 (m, 2H), 7.63-7.56 (m, 3H), 7.00-6.89 (m, 3H), 4.20 (s, 2H), 3.63-3.11 (m, 8H), 2.84 (s, 2H). LC-ESI-MS (+) m/z = 632.9 [M+Na+]+. HRMS-ESI [M+H+]+ m/z calculated for [C28H24FIN403]+ 611.0955, found 611.0971.
  • 2
  • [ 763111-47-3 ]
  • [ 108466-89-3 ]
  • tert-butyl (2-(2-(2-(4-(2-fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoyl)piperazin-1-yl)-2-oxoethoxy)ethoxy)ethyl)carbamate [ No CAS ]
  • 3
  • [ 763111-47-3 ]
  • [ 158690-56-3 ]
  • C27H32FN5O4 [ No CAS ]
YieldReaction ConditionsOperation in experiment
With N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 70℃; for 12h; General procedure: Step 1 (N-alkylation): To a solution of alkyl tosylate (0.5 mmol,1.3 equiv) in DMF (1.5 mL) was added phthalazinone (0.37mmol, 1 equiv) and DIPEA (0.75 mmol, 2.0 equiv) and stirred for12 hours at 70 C. After the reaction was completed, water andEtOAc were added to the residue. The organic layer was separated,filtered and evaporated. The reaction mixture was purifiedby flash silica gel column chromatography using MeOH/DCM 8% as the eluent to afford the desired products. Step 2 (Boc deprotection): A solution of Boc-protected substratesin DCM was treated with 4 N HCl in 1,4-dioxane solution(1 mL). The reaction mixture stirred at room temperature for 30min. The reaction mixture was concentrated under reducedpressure to afford the product as a pale yellow solid that wasused in the next step without purification. Step 3 (Amide coupling): HATU (0.11 mmol,1.1 equiv) and DIPEA(0.4 mmol, 4 equiv) were added to a solution of amine (0.1mmol) and carboxylic acid (0.1 mmol, 1 equiv) in DMF andstirred for 12 hours at room temperature. After the reactionwascomplete, water and EtOAc were added to the residue. Theorganic layer was separated, filtered and evaporated. The reactionmixture was purified by flash silica gel column chromatographyusing MeOH/DCM 8% as the eluent to afford thedesired products.
With N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 70℃; for 12h; General procedure: In the solution of alkyl tosylate (0.5 mmol, 1.3 equivalents) of DMF (1.5 mL), phthalazinone (0.37 mmol, 1 eq) and DIPEA (0.75 mmol, 2.0 equivalents) were added, and stirred for 70 degrees to 12 hours. After the reaction was finalized, water and EtOAc were added to the residue. The organic layer was separated, filtered, and evaporated. The reaction mixture was purified with flash silica gel column chromatography using MeOH / DCM 8% as an elution agent to obtain the target product.
Recommend Products
Same Skeleton Products

Technical Information

Historical Records

Related Functional Groups of
[ 763111-47-3 ]

Fluorinated Building Blocks

Chemical Structure| 1242156-59-7

[ 1242156-59-7 ]

6-(tert-Butyl)-8-fluorophthalazin-1(2H)-one

Similarity: 0.77

Chemical Structure| 1021298-68-9

[ 1021298-68-9 ]

2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzonitrile

Similarity: 0.76

Chemical Structure| 23928-52-1

[ 23928-52-1 ]

7-Fluorophthalazin-1(2H)-one

Similarity: 0.71

Chemical Structure| 763114-26-7

[ 763114-26-7 ]

2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid

Similarity: 0.67

Chemical Structure| 230301-83-4

[ 230301-83-4 ]

5-Fluoro-3,4-dihydroisoquinolin-1(2H)-one

Similarity: 0.64

Aryls

Chemical Structure| 1021298-68-9

[ 1021298-68-9 ]

2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzonitrile

Similarity: 0.76

Chemical Structure| 763114-26-7

[ 763114-26-7 ]

2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid

Similarity: 0.67

Chemical Structure| 446-24-2

[ 446-24-2 ]

2-Fluorobenzohydrazide

Similarity: 0.64

Chemical Structure| 53242-88-9

[ 53242-88-9 ]

4-(4-Chlorobenzyl)phthalazin-1(2H)-one

Similarity: 0.62

Chemical Structure| 24167-56-4

[ 24167-56-4 ]

4-Fluoro-N,N-dimethylbenzamide

Similarity: 0.61

Amides

Chemical Structure| 1242156-59-7

[ 1242156-59-7 ]

6-(tert-Butyl)-8-fluorophthalazin-1(2H)-one

Similarity: 0.77

Chemical Structure| 1021298-68-9

[ 1021298-68-9 ]

2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzonitrile

Similarity: 0.76

Chemical Structure| 23928-52-1

[ 23928-52-1 ]

7-Fluorophthalazin-1(2H)-one

Similarity: 0.71

Chemical Structure| 763114-26-7

[ 763114-26-7 ]

2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid

Similarity: 0.67

Chemical Structure| 230301-83-4

[ 230301-83-4 ]

5-Fluoro-3,4-dihydroisoquinolin-1(2H)-one

Similarity: 0.64

Related Parent Nucleus of
[ 763111-47-3 ]

Piperazines

Chemical Structure| 13754-38-6

[ 13754-38-6 ]

1-Benzoylpiperazine

Similarity: 0.55

Chemical Structure| 27469-60-9

[ 27469-60-9 ]

4,4-Difluorobenzhydrylpiperazine

Similarity: 0.52

Chemical Structure| 5368-20-7

[ 5368-20-7 ]

4-Methyl-3-phenylpiperazin-2-one

Similarity: 0.52

Phthalazines

Chemical Structure| 1242156-59-7

[ 1242156-59-7 ]

6-(tert-Butyl)-8-fluorophthalazin-1(2H)-one

Similarity: 0.77

Chemical Structure| 1021298-68-9

[ 1021298-68-9 ]

2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzonitrile

Similarity: 0.76

Chemical Structure| 23928-52-1

[ 23928-52-1 ]

7-Fluorophthalazin-1(2H)-one

Similarity: 0.71

Chemical Structure| 763114-26-7

[ 763114-26-7 ]

2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl)benzoic acid

Similarity: 0.67

Chemical Structure| 53242-88-9

[ 53242-88-9 ]

4-(4-Chlorobenzyl)phthalazin-1(2H)-one

Similarity: 0.62

; ;